2Gottlieb AB, Lebivohl M, Shirin S, et al. Anti-CD4 monoelonal antibody treatment of moderate to severe psoriasis vulgaris : results of a pilot, multicenter,multiple-dose,placebo-controlled study. J Am Acad Dermatol, 2000,43:595-604.
3Mak RK, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis [J].Actas dermo-sifiliograficas, 2009,100 Suppl 2: 2-13.
4Kim J, Krueger JG. The immunopathogenesis of psoriasis [J]. Dermatologic clinics, 2015,33 ( 1 ) : 13 -23.
5Krueger JG.The immunologic basis for the treatment of psoriasis with new biologic agents [ J] .Journal of the American Academy of Dermatology,2002,46( 1 ) : 1-23 ; quiz -6.
6Kastelan M, Massari LP, Pasic A, et al. New trends in the immunopathogenesis of psoriasis [J]. Acta dermatovenerologica Croatica ,2004,12( 1 ) : 26-29.
8Krneger G, Ellis CN.Psoriasis--recent advances in understanding its pathogenesis and treatment [ J ]. Journal of the American Academy of Dermatology,2005,53( 1 Suppl 1 ) : s94-100.
9Di Cesare A,Di Meglio P, Nestle FO.The IL-23/Th17 axis in the immunopathogenesis of psoriasis [J]. The Journal of investigative dermatology,2009, 129 (6) : 1339-1350. doi: 10. 1038/jid. 2009. 5Q.
10Noma T. Helper T cell paradigm: Thl7 and regulatory T cells involved in autoimmune inflammatory disorders, pathogen defense and allergic diseases [J]. Nihon Rinsho Meneki Gakkai Kaishi, 2010,33(5) :262-271.
